Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest - Schedule of Noncontrolling Interest (Details)

v3.20.2
Stockholders' Equity, Common Stock Purchase Warrants, and Noncontrolling Interest - Schedule of Noncontrolling Interest (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
NCI - equity (deficit) - beginning of period     $ (814)    
Net loss attributable to NCI $ (266) $ (145) (702) $ (314)  
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan 513 356 840 706  
NCI - equity (deficit) - end of period (1,485)   (1,485)   $ (814)
Non-controlling Interest [Member]          
NCI - equity (deficit) - beginning of period     (814) (162) (162)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan  
NCI - equity (deficit) - end of period $ (1,485)   (1,485)   (814)
Non-controlling Interest [Member] | Solys Diagnostics Inc. [Member]          
Minority Interest investment in Solys Diagnostics Inc       889
Minority Interest share subscription receivable - Solys Diagnostics Inc.       (889)
Net loss attributable to NCI     (62)   (10)
Non-controlling Interest [Member] | Lucid Diagnostics Inc [Member]          
Minority Interest Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise     5  
Net loss attributable to NCI     (640)   (801)
Stock-based compensation expense - Lucid Diagnostics Inc 2018 Equity Plan     $ 26   $ 159